Quarterly ResultAug 6, 2026, 04:11 PM
Nutex Health Q2 Net Income $65.8M; EPS $9.58; HaloMD Impact
AI Summary
Nutex Health Inc. reported a significant turnaround in its second quarter 2026 financial results, with net income attributable to the company reaching $65.8 million, a substantial increase from a loss in the prior year. Basic earnings per share rose to $9.58. These improvements were partly driven by an amendment to the HaloMD contract and a reduction in CMS IDR fees, which positively impacted contract services expense by $52.3 million.
Key Highlights
- Net income attributable to Nutex Health Inc. was $65.8 million in Q2 2026, up from $(17.7) million in Q2 2025.
- Basic EPS was $9.58 in Q2 2026, compared to $(2.95) in Q2 2025.
- Total revenue for Q2 2026 was $210.8 million, down from $244.0 million in Q2 2025.
- HaloMD contract amendment and CMS fee reduction reduced contract services expense by $52.3 million.
- This change increased net income attributable to Nutex Health Inc. by $25.0 million for Q2 2026.
- Net cash provided by operating activities for YTD 2026 was $109.7 million, up from $78.2 million YTD 2025.
- Total equity increased to $507.3 million as of June 30, 2026, from $423.4 million at year-end 2025.
Price Impact
More from NUTX